Resources

Insights, technical notes, and case studies.

[ Insight ]

Antibody Characterization by Liquid Chromatography and Mass Spectrometry (LC-MS/MS)

Comprehensive LC-MS/MS workflows — intact mass, subunit mass, peptide mapping, glycosylation, and sequence variant analysis — for antibody quality control, developability assessment, and production optimization.

2026

[ Insight ]

Triaging Diverse Antibody Candidates

Triaging diverse antibody candidates enables efficient triage of antibody therapeutics against a target of interest using both in vitro and in silico properties to prioritize the best candidates and reduce bench workload.

2026

[ Insight ]

Why Early Antibody Developability Assessment Matters?

Discover why early antibody developability assessment is critical for identifying liabilities, reducing development risk, improving candidate selection, and accelerating therapeutic success.

2026

[ Technical Note ]

Computational Approaches to Antibody Humanization

An overview of in silico frameworks for CDR grafting and sequence optimization — humanization strategies, structural considerations (CSRs, Vernier zone, CDR stem residues), framework ranking, and germline-library scoring.

2026

[ Technical Note ]

H3 Loop Modeling for VHH, scFv, and Fab Formats

Refinement strategies, accuracy benchmarks, and tooling guidance for the most variable CDR region.

2024

[ Case Study ]

In Silico Residue Scanning Guides Affinity Maturation

Using Schrödinger BioLuminate to systematically scan interface residues and identify tunable positions for affinity improvement.

2026

[ Case Study ]

From Aggregation Hotspot Prediction to Risk Mitigation: Improving MEDI-1912 Developability

Structure-guided aggregation risk mitigation using Schrödinger BioLuminate to improve antibody developability and reduce aggregation propensity.

2026

[ Case Study ]

AI-Driven Mapping of the HER2-Herceptin Antibody-Antigen Interface

Using AI-driven structural modeling, we mapped the HER2-Herceptin antibody-antigen interface to identify critical binding determinants and accelerate data-driven antibody development.

2026

[ Case Study ]

High-Throughput Antibody Expression Optimization

A scalable workflow for rapidly screening, expressing, and selecting high-quality antibody candidates for downstream development.

2026